Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Publishes Phase I Data on ATTR Drugs

Premium

Alnylam Pharmaceuticals and collaborators this week published data from phase I trials of the siRNA-based transthyretin amyloidosis drugs ALN-TTR01 and ALN-TTR02 in the New England Journal of Medicine.

The data, which had previously been released by the company (GSN 12/01/2011 & 7/19/2012), show that RNAi-based drugs can achieve rapid, dose-dependent, durable, and specific knockdown of the mutant protein that causes the disease, Alnylam said.

The paper can be found here.

"The phase I studies of ALN-TTR01 and ALN-TTR02 demonstrate key human proof of concept for RNAi therapeutics targeting TTR but also for liver-expressed target genes in general," Alnylam CMO Akshay Vaishnaw said in a statement.

"This new paper describes our clinical trial experience with ALN-TTR01 and ALN-TTR02, which utilize first- and second-generation lipid nanoparticle formulations, respectively," Alnylam Vice President of Clinical Research Jared Gollob added. "We believe the findings published today … suggest that the robust, sustained knockdown of TTR levels observed in our clinical trials with ALN-TTR02 may ameliorate the course of disease in patients with ATTR."

Alnylam has stopped development of ALN-TTR01 in order to focus on ALN-TTR02, which is poised to enter phase III testing before the end of this year. The company is also working on a subcutaneously delivered version of the drug, called ALN-TTRsc, that is slated to enter phase II by the end of 2013.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.